Bryan Howcroft joined MediPharm Labs Corp., a pharmaceutical company specialized in precision-based cannabinoids, as chief executive officer and director.
Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new pharmaceutical business that will be based in Switzerland.
The Center for Breakthrough Medicines (CBM) appointed Joerg Ahlgrimm CEO.
Kaia Health appointed Nigel Ohrenstein – healthcare entrepreneur and Lumeris co-founder – as president to accelerate the growth and further advance the digital therapeutics company’s strategy as the market leader in musculoskeletal (MSK) care.
Harpoon Therapeutics Inc., a clinical stage immunotherapy company developing a novel class of T cell engagers, announced that Julie Eastland was named president and chief executive officer.
Insilico Medicine, an end-to-end AI-powered drug discovery company, appointed Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical pipeline assets.
Sandy J. Falk, MD, was named editor-in-chief of The Merck Manuals, a digital medical reference available for free to all online at MerckManuals.com and as mobile apps with versions for healthcare professionals and consumers.
Impact Therapeutics made Dr. Chun-Pyn Shen head of Regulatory Affairs, VP.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd., chose Janna Hutz, Ph.D., as president of the Eisai Center for Genetics Guided Dementia Discovery (G2D2).
Locanabio Inc., an RNA-targeting gene therapy company, appointed Kat Lange as chief financial officer.
